Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to determine the potential utility of a novel algorithm to calculate individual GFR values in cancer patients. Based on carboplatin AUC measurements the algorithm-based values were compared with results related to other routinely used equations.

Methods

The association between measured and predicted carboplatin AUC was examined by the Bland–Altman analysis to determine bias and precision. Based on the Calvert formula, GFR values assessed by different routes of calculation including the novel algorithm were compared with each other in individual patients.

Results

The mean absolute administered carboplatin dose was 498 mg and the mean measured carboplatin AUC 5.8 mg/ml × min. Compared to the novel algorithm, the degree of bias to calculate carboplatin AUC was greater with the Cockcroft-Gault, Chatelut, Hoek and Schmitt formula which includes cystatin C as a parameter. In selected patients, algorithm-based GFR values were closer to GFR according to the Calvert formula than results of other equations, including the Jelliffe formula.

Conclusion

These results suggest that the concept of a non cystatin C-based novel algorithm including three different formulas rather than one single equation may improve accurate estimation of GFR over a broad range of constitutive values, including patients with low constitutive renal function as well as overweight patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147

    Article  PubMed  CAS  Google Scholar 

  2. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of cis-diammine(1, 1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44:5432–5438

    PubMed  CAS  Google Scholar 

  3. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520–528

    PubMed  CAS  Google Scholar 

  4. Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ, Sridhara R (1993) Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11:1156–1164

    PubMed  CAS  Google Scholar 

  5. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756

    PubMed  CAS  Google Scholar 

  6. Calvert AH, Boddy A, Bailey NP, Siddiqui N, Humphreys A, Hughes A, Robson L, Gumbrell L, Thomas H, Chapman F (1995) Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 22:91–98

    PubMed  CAS  Google Scholar 

  7. Marx GM, Blake GM, Galani E, Steer CB, Harper SE, Adamson KL, Bailey DL, Harper PG (2004) Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 15:291–295

    Article  PubMed  CAS  Google Scholar 

  8. Poole SG, Dooley MJ, Rischin D (2002) A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. Ann Oncol 13:949–955

    Article  PubMed  CAS  Google Scholar 

  9. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    Article  PubMed  CAS  Google Scholar 

  10. Jelliffe RW (1973) Letter: Creatinine clearance: bedside estimate. Ann Intern Med 79:604–605

    PubMed  CAS  Google Scholar 

  11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470

    PubMed  CAS  Google Scholar 

  12. Salazar DE, Corcoran GB (1988) Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 84:1053–1060

    Article  PubMed  CAS  Google Scholar 

  13. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH (2001) Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84:452–459

    Article  PubMed  CAS  Google Scholar 

  14. Holweger K, Lipp HP, Dietz K, Hartmann JT, Bokemeyer C (2008) Novel algorithm for more accurate calculation of renal function in adults with cancer. Ann Pharmacother 42:1749–1757

    Article  PubMed  CAS  Google Scholar 

  15. Hoek FJ, Kemperman FA, Krediet RT (2003) A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 18:2024–2031

    Article  PubMed  CAS  Google Scholar 

  16. Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E (2009) A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 15:3633–3639

    Article  PubMed  CAS  Google Scholar 

  17. Sorensen BT, Stromgren A, Jakobsen P, Jakobsen A (1993) A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31:324–327

    Article  PubMed  CAS  Google Scholar 

  18. van Warmerdam LJC, van Tellingen O, Maes RAA, Beijnen JH (1995) Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 351:777–781

    Article  Google Scholar 

  19. Du BD, Du Bois EF (1919) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5:303–311

    Google Scholar 

  20. Chatelut E, Dezeuze A, Lavit M, Chevreau C, Pujol A, Boneu A, Roche H, Houin G, Bugat R, Canal P (1995) Prediction of carboplatin clearance from morphological and biological patient characteristics. Bull Cancer 82:946–953

    PubMed  CAS  Google Scholar 

  21. Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38:1933–1953

    PubMed  CAS  Google Scholar 

  22. Corcoran RM, Durnan SM (1977) Albumin determination by a modified bromcresol green method. Clin Chem 23:765–766

    PubMed  CAS  Google Scholar 

  23. Finney H, Newman DJ, Gruber W, Merle P, Price CP (1997) Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 43:1016–1022

    PubMed  CAS  Google Scholar 

  24. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307–310

    Article  PubMed  CAS  Google Scholar 

  25. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M (2007) International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43:14–34

    Article  PubMed  Google Scholar 

  26. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G (2007) Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110:1376–1384

    Article  PubMed  CAS  Google Scholar 

  27. Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483

    Article  PubMed  CAS  Google Scholar 

  28. Holweger K, Bokemeyer C, Lipp HP (2005) Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge. J Cancer Res Clin Oncol 131:559–567

    Article  PubMed  Google Scholar 

  29. Dooley MJ, Poole SG, Rischin D, Webster LK (2002) Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 38:44–51

    Article  PubMed  CAS  Google Scholar 

  30. Ekhart C, de Jonge Milly E, Huitema Alwin DR, Schellens JHM, Rodenhuis S, Beijnen Jos H (2006) Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res 12:6502–6508

    Article  PubMed  CAS  Google Scholar 

  31. Bookstaver PB, Johnson JW, McCoy TP, Stewart D, Williamson JC (2008) Modification of Diet in Renal Disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination. Ann Pharmacother 42:1758–1765

    Article  PubMed  CAS  Google Scholar 

  32. Kos J, Stabuc B, Cimerman N, Brunner N (1998) Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 44:2556–2557

    PubMed  CAS  Google Scholar 

  33. Louvar DW, Rogers TB, Bailey RF, Matas AJ, Ibrahim HN (2007) Cystatin C is not superior to creatinine-based models in estimating glomerular filtration rate in former kidney donors. Transplantation 84:1112–1117

    Article  PubMed  Google Scholar 

  34. Donadio C, Lucchesi A, Ardini M, Cosio S, Fanucchi A, Gadducci A (2009) Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer. Ther Drug Monit 31:63–69

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Karin Holweger is supported by an educational grant from Amgen Germany.

Author information

Authors and Affiliations

  1. Department of Hospital Pharmacy, Roentgenweg 9, 72076, Tuebingen, Germany

    Karin Holweger & Hans-Peter Lipp

  2. Department of Pharmacy, Slotervaart Hospital Amsterdam, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands

    Jos H. Beijnen

  3. Internal Medicine-Oncology-Hematology, University Medical Center Eppendorf, Martinistr. 52, 20251, Hamburg, Germany

    Carsten Bokemeyer

  4. Internal Medicine-Oncology-Hematology, Comprehensive Cancer Center North, Christian-Albrecht-University of Kiel, Arnold-Heller-Str. 3, 24105, Kiel, Germany

    Joerg Thomas Hartmann

Authors
  1. Karin Holweger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans-Peter Lipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jos H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carsten Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joerg Thomas Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karin Holweger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holweger, K., Lipp, HP., Beijnen, J.H. et al. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin. Cancer Chemother Pharmacol 68, 693–701 (2011). https://doi.org/10.1007/s00280-010-1537-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1537-0

Keywords

Search

Navigation